サバラ
Savara Inc.
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.16 | $0 | -$30M |
| 2026 Q1 | -0.15 | $0 | -$33M |
| 2025 Q4 | -0.13 | $0 | -$25M |
| 2025 Q3 | -0.14 | $0 | -$23M |
| 2025 Q2 | -0.14 | $0 | -$26M |
| 2025 Q1 | -0.12 | $0 | -$27M |
| 2024 Q4 |
| -0.14 |
| $0 |
| -$23M |
| 2024 Q3 | -0.11 | $0 | -$23M |